Camber Capital Management LP Mirati Therapeutics, Inc. Transaction History

Camber Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$27.8 - $45.35 $8.34 Million - $13.6 Million	-300,000 Reduced 16.67%	1,500,000 $65.3 Million
Q2 2023 Aug 14, 2023	BUY	$36.13 - $49.49 $14.5 Million - $19.8 Million	400,000 Added 28.57%	1,800,000 $65 Million
Q4 2022 Feb 14, 2023	SELL	$41.27 - $98.62 $24.8 Million - $59.2 Million	-600,000 Reduced 30.0%	1,400,000 $63.4 Million
Q3 2022 Nov 14, 2022	BUY	$59.5 - $86.7 $80.3 Million - $117 Million	1,350,000 Added 207.69%	2,000,000 $140 Million
Q2 2022 Aug 15, 2022	SELL	$39.16 - $88.71 $21.5 Million - $48.8 Million	-550,000 Reduced 45.83%	650,000 $43.6 Million
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $47.4 Million - $94.4 Million	625,000 Added 108.7%	1,200,000 $98.7 Million
Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $16.5 Million - $23.8 Million	125,000 Added 27.78%	575,000 $84.3 Million
Q3 2021 Nov 15, 2021	BUY	$132.13 - $177.45 $6.61 Million - $8.87 Million	50,000 Added 12.5%	450,000 $79.6 Million
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $39.6 Million - $49.4 Million	275,000 Added 220.0%	400,000 $64.6 Million
Q1 2021 May 17, 2021	BUY	$158.92 - $221.61 $19.9 Million - $27.7 Million	125,000 New	125,000 $21.4 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Camber Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Camber Capital Management LP with notifications on news.